Search

Your search keyword '"Mitchel, Yale"' showing total 245 results
Start Over Author "Mitchel, Yale"
245 results on '"Mitchel, Yale"'

1. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Author

Fitter, Heather D., Illoh, Kachikwu, Cavanaugh, Kenneth J., Jr., Scirica, Benjamin M., Irony, Ilan, Brown Kichline, Rachel E., Levine, Jonathan G., Park, Anna, Sacks, Leonard, Szarfman, Ana, Unger, Ellis F., Wachter, Lori Ann, Zuckerman, Bram, Mitchel, Yale, Peddicord, Douglas, Shook, Thomas, Kisler, Bron, Jaffe, Charles, Bartley, Rhonda, DeMets, David L., Mencini, MariJo, Janning, Cheri, Bai, Steve, Lawrence, John, D’Agostino, Ralph B., Sr., Pocock, Stuart J., Hicks, Karen A., Mahaffey, Kenneth W., Mehran, Roxana, Nissen, Steven E., Wiviott, Stephen D., Dunn, Billy, Solomon, Scott D., Marler, John R., Teerlink, John R., Farb, Andrew, Morrow, David A., Targum, Shari L., Sila, Cathy A., Thanh Hai, Mary T., Jaff, Michael R., Joffe, Hylton V., Cutlip, Donald E., Desai, Akshay S., Lewis, Eldrin F., Gibson, C. Michael, Landray, Martin J., Lincoff, A. Michael, White, Christopher J., Brooks, Steven S., Rosenfield, Kenneth, Domanski, Michael J., Lansky, Alexandra J., McMurray, John J.V., Tcheng, James E., Steinhubl, Steven R., Burton, Paul, Mauri, Laura, O’Connor, Christopher M., Pfeffer, Marc A., Hung, H.M. James, Stockbridge, Norman L., Chaitman, Bernard R., and Temple, Robert J.

Published
2018
Full Text
View/download PDF

2. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol

Author

Ballantyne, Christie M., Shah, Sukrut, Sapre, Aditi, Ashraf, Tanya B., Tobias, Sandra C., Sahin, Tayfun, Ye, Ping, Dong, Yugang, Sheu, Wayne Huey-Heng, Kang, Duk-Hyun, Ferreira Rossi, Paulo Roberto, Moiseeva, Yulia, Briones, Ignacio Rodriguez, Johnson-Levonas, Amy O., and Mitchel, Yale B.

Published
2017
Full Text
View/download PDF

4. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616

Author

Ballantyne, Christie M., primary, Banka, Puja, additional, Mendez, Gustavo, additional, Garcia, Raymundo, additional, Rosenstock, Julio, additional, Rodgers, Anthony, additional, Mendizabal, Geraldine, additional, Mitchel, Yale, additional, and Catapano, Alberico L., additional

Published
2023
Full Text
View/download PDF

7. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

Author

Gerstman, M., Howes, L., Kostner, K., Nestel, P., Sullivan, D., Brath, H., Patsch, J., Paulweber, B., Toplak, H., Constance, C.M., Howlett, E., Mymin, D., Pliamm, L., Saunders, K.K., Tardif, J.-C., Tytus, R., Aschner, P., Keinänen-Klukaanniemi, S., Strandberg, T., Taskinen, M.-R., Luc, G., Richter, D., Schlienger, J.L., Zaïr, Y., Appel, K.-F., Baar, M., Luley, C., Overhoff, U., Pomykaj, T., Schaefer, T., Lau, S.T., Lee, K.L.F., Tan, K., Tomlinson, B., Tsang, M.W., Badacsonyi, K., Kalina, Á., Kanakaridisz, N., Márk, L., Péterfai, É., Regos, L., Reiber, I., Takács, J., Vértes, A., Elis, A., Gavish, D., Harats, D., Hussein, O., Hayek, T., Leitersdorf, E., Bin Abdul Ghapar, A.K., Chee, K.H., Ismail, S.B., Ling, K.H., Ramanathan, G.R.L., Sim, K.H., Alvarado, R., Benavides, M., Cardona, G.E., Gonzalez, G., Verdejo, J., Basart, D.C.G., Imholz, B.P.M., Jonker, J.J.C., Nierop, P.R., Posma, J.L., Twickler, Th.B., Barrington-Ward, E., Cutfield, R., Friedlander, D.H., Scott, R.S., Istad, H., Langslet, G., Skjelvan, G.K., Campodónico Hoyos, S.J., Coloma Araniya, R., Gallegos C., A., Pino Morales, C.A., Watanabe, L., Arutyunov, G.P., Blokhin, A.B., Bubnova, M.G., Marcevich, S.Y., Álvarez Sánchez, C., Álvarez-Sala Walther, L.A., Gil Extremera, B., Perez Jimenez, F., de Teresa Parreño, L., Anderberg, C.-P., Hedin, U., Hellberg, A., Höök, P., Kjellström, T., Nilsson, P., Olsson, A.G., Rosenqvist, U., Tolagen, K., Wolff, T., Baskin, A., Bays, H.E., Bernstein, R.I., Bittar, N., Brinton, E.A., Chee, L.H.K., Cottiero, R.A., D'Agostino, R.D., Davidson, M.H., Denker, P.S., Garcia, R.K., Hippert, R.K., Isakov, T., Kaster, S.R., Kerzner, B., Klein, E.J., Koren, M.J., Kutner, M.E., Liljenquist, D., Lorch, D.G., Jr., Lorraine, R., Lubin, B.C., Lunde, N.M., Majchrzak, T.J., McKenney, J.M., Mukherjee, S., Muse, D.D., Otruba, M.S., Pappas, J.E., Patrick, K., Powell, S.J., Riffer, E., Rink, L.D., Rohlf, J.L., Rosen, J.B., Rosenbilt, P.D., Roth, E.M., Rubenstein, C.J., Rubino, J., Rudolph, L.A., Schneider, A., Short, W.G., Silverfield, J.C., Suresh, D.P., Tarshis, G.A., Toth, P.D., Townsend, R.W., Wahl, T.O., Brinton, Eliot A., Kher, Uma, Shah, Sukrut, Cannon, Christopher P., Davidson, Michael, Gotto, Antonio M., Ashraf, Tanya B., McCrary Sisk, Christine, Dansky, Hayes, Mitchel, Yale, and Barter, Philip

Published
2015
Full Text
View/download PDF

18. Safety of anacetrapib in patients with or at high risk for coronary heart disease

Author

Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M. Jr., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, and Barter, Philip

Subjects
Anacetrapib -- Usage, Anacetrapib -- Health aspects, Cholesterol -- Health aspects, Coronary heart disease -- Drug therapy
Abstract

A study was conducted to evaluate the efficacy and safety of anacetrapib in patients with or at high risk for coronary heart disease. Results indicated that anacetrapib treatment was found to be quite safe as well as effective on LDL and HDL cholesterol.

Published
2010

26. Evaluation of Sustained/Controlled-Release Dosage Forms of 3-Hydroxy-3-methylglutaryl–Coenzyme A (HMG-CoA) Reductase Inhibitors in Dogs and Humans

Author

Cheng, Haiyung, Sutton, Steven C., Pipkin, James D., Zentner, Gaylen M., Rogers, J. Douglas, Schwartz, Jules I., Mitchel, Yale B., Grasing, Kenneth, Schwartz, Michael S., Amin, Raju D., Liu, Lida, Ebel, David L., Coulter, Amy, Engle, Karen, McClelland, Gregory A., Lui, Chung Y., and Rork, Gerald S.

Published
1993
Full Text
View/download PDF

37. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial

Author

Illingworth, D. Roger, Stein, Evan A., Mitchel, Yale B., Dujovne, Carlos A., Frost, Philip H., Knopp, Robert H., Tun, Peggy, Zupkis, Robert V., and Greguski, Roger A.

Subjects
Hypercholesterolemia -- Drug therapy, Lovastatin -- Evaluation, Niacin -- Evaluation, Health
Abstract

Background: Niacin and lovastatin are both effective drugs for the treatment of hypercholesterolemia and are among the drugs of first choice recommended by the adult treatment panel. To date, however, no studies have directly compared the lipoprotein-modifying effects and safety of lovastatin and niacin across their usual dosage range in patients with primary hypercholesterolemia. Methods: The efficacy and safety of lovastatin and niacin were compared in a controlled, randomized, open-label study of 26 weeks' duration that was conducted at five lipid clinics. One hundred thirty-six patients with primary hypercholesterolemia participated in the study. Entry criteria were a low-density lipoprotein (LDL) cholesterol level greater than 4.37 mmol/L (160 mg/dL) with coronary heart disease and/or more than two coronary heart disease risk factors or an LDL cholesterol level greater than 5.19 mmol/L (190 mg/dL) in patients without coronary heart disease or less than two coronary heart disease risk factors. The study consisted of a 4-week diet run-in period after which eligible patients were randomly assigned to receive treatment with either lovastatin (20 mg/d) or niacin (1.5 g/d) for 10 weeks. On the basis of the LDL cholesterol response and patient tolerance, the doses were sequentially increased to 40 and 80 mg/d of lovastatin or 3 and 4.5 g/d of niacin after 10 and 18 weeks of treatment, respectively. Results: In the two patient groups, 66% of patients treated with lovastatin and 54% of patients treated with niacin underwent full dosage titration. At all time points, lovastatin was significantly (P

Published
1994

39. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Author

Hicks, Karen A., primary, Mahaffey, Kenneth W., additional, Mehran, Roxana, additional, Nissen, Steven E., additional, Wiviott, Stephen D., additional, Dunn, Billy, additional, Solomon, Scott D., additional, Marler, John R., additional, Teerlink, John R., additional, Farb, Andrew, additional, Morrow, David A., additional, Targum, Shari L., additional, Sila, Cathy A., additional, Thanh Hai, Mary T., additional, Jaff, Michael R., additional, Joffe, Hylton V., additional, Cutlip, Donald E., additional, Desai, Akshay S., additional, Lewis, Eldrin F., additional, Gibson, C. Michael, additional, Landray, Martin J., additional, Lincoff, A. Michael, additional, White, Christopher J., additional, Brooks, Steven S., additional, Rosenfield, Kenneth, additional, Domanski, Michael J., additional, Lansky, Alexandra J., additional, McMurray, John J.V., additional, Tcheng, James E., additional, Steinhubl, Steven R., additional, Burton, Paul, additional, Mauri, Laura, additional, O’Connor, Christopher M., additional, Pfeffer, Marc A., additional, Hung, H.M. James, additional, Stockbridge, Norman L., additional, Chaitman, Bernard R., additional, Temple, Robert J., additional, Fitter, Heather D., additional, Illoh, Kachikwu, additional, Cavanaugh, Kenneth J., additional, Scirica, Benjamin M., additional, Irony, Ilan, additional, Brown Kichline, Rachel E., additional, Levine, Jonathan G., additional, Park, Anna, additional, Sacks, Leonard, additional, Szarfman, Ana, additional, Unger, Ellis F., additional, Wachter, Lori Ann, additional, Zuckerman, Bram, additional, Mitchel, Yale, additional, Peddicord, Douglas, additional, Shook, Thomas, additional, Kisler, Bron, additional, Jaffe, Charles, additional, Bartley, Rhonda, additional, DeMets, David L., additional, Mencini, MariJo, additional, Janning, Cheri, additional, Bai, Steve, additional, Lawrence, John, additional, D’Agostino, Ralph B., additional, and Pocock, Stuart J., additional

Published
2018
Full Text
View/download PDF

40. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention

Author

Bohula, Erin A., primary, Morrow, David A., additional, Giugliano, Robert P., additional, Blazing, Michael A., additional, He, Ping, additional, Park, Jeong-Gun, additional, Murphy, Sabina A., additional, White, Jennifer A., additional, Kesaniemi, Y. Antero, additional, Pedersen, Terje R., additional, Brady, Adrian J., additional, Mitchel, Yale, additional, Cannon, Christopher P., additional, and Braunwald, Eugene, additional

Published
2017
Full Text
View/download PDF

41. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

Author

Brinton, Eliot A., primary, Triscari, Joseph, additional, Brudi, Philippe, additional, Chen, Erluo, additional, Johnson-Levonas, Amy O., additional, Sisk, Christine McCrary, additional, Ruck, Rae Ann, additional, MacLean, Alexandra A., additional, Maccubbin, Darbie, additional, and Mitchel, Yale B., additional

Published
2016
Full Text
View/download PDF

42. ATHEROTHROMBOTIC RISK STRATIFICATION AND EZETIMIBE USE IN IMPROVE-IT

Author

May, Erin Ann Bohula, primary, Morrow, David, additional, Cannon, Christopher, additional, Giugliano, Robert, additional, Blazing, Michael, additional, He, Ping, additional, Murphy, Sabina, additional, Jennifer, White, additional, Kesaniemi, Antero, additional, Pedersen, Terje, additional, Brady, Adrian J., additional, Mitchel, Yale B., additional, Tershakovec, Andrew, additional, and Braunwald, Eugene, additional

Published
2016
Full Text
View/download PDF

43. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Author

Bays,Harold, Brinton,Eliot, Triscari,Joseph, Chen,Erluo, Maccubbin,Darbie, MacLean,Alexandra A, Gibson,Kendra, Ruck,Rae Ann, Johnson-Levonas,Amy O, O'Neill,Edward A, Mitchel,Yale, Bays,Harold, Brinton,Eliot, Triscari,Joseph, Chen,Erluo, Maccubbin,Darbie, MacLean,Alexandra A, Gibson,Kendra, Ruck,Rae Ann, Johnson-Levonas,Amy O, O'Neill,Edward A, and Mitchel,Yale

Abstract

Harold E Bays,1 Eliot A Brinton,2 Joseph Triscari,3 Erluo Chen,3 Darbie Maccubbin,3 Alexandra A MacLean,3 Kendra L Gibson,3 Rae Ann Ruck,3 Amy O Johnson-Levonas,3 Edward A O’Neill,3 Yale B Mitchel3 1Louisville Metabolic & Atherosclerosis Research Center (L-MARC), Louisville, KY, USA; 2Utah Foundation for Biomedical Research, Salt Lake City, UT, USA; 3Merck & Co, Inc., Whitehouse Station, NJ, USA Background: The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents. Objective: Evaluate the lipid-modifying efficacy of extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2DM with better or poorer glycemic control. Methods: Post hoc analysis of clinical trial data from patients with T2DM who were randomized 4:3 to double-blind ERN/LRPT or placebo (n=796), examining the lipid-modifying effects of ERN/LRPT in patients with glycosylated hemoglobin or fasting plasma glucose levels above and below median baseline levels. Results: At Week 12 of treatment, ERN/LRPT significantly improved low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a), compared with placebo, with equal efficacy in patients above or below median baseline glycemic control. Compared with placebo, over 36 weeks of treatment more patients treated with ERN/LRPT had worsening of their diabetes and required intensification of antihyperglycemic medication, irrespective of baseline glycemic control. Incidences of other adverse experiences were generally low in all treatment groups. Conclusion: The lipid-modifying effects of ERN/LRPT are independent of the degree of baseline glycemic control in patients with T2DM (NCT00485758). Keywords: lipid-modifying agents, hyperglycemia, LDL, HDL, triglycerides

Published
2015

44. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Author

Mitchel, Yale, primary, Bays, Harold E., additional, Brinton, Eliot A., additional, Triscari, Joseph, additional, Chen, Erluo, additional, Maccubbin, Darbie, additional, MacLean, Alexandra A., additional, Gibson, Kendra, additional, Ruck, Rae Ann, additional, Johnson-Levonas, Amy O., additional, and O'Neill, Edward A., additional

Published
2015
Full Text
View/download PDF

45. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

Author

Brinton, Eliot A., primary, Kher, Uma, additional, Shah, Sukrut, additional, Cannon, Christopher P., additional, Davidson, Michael, additional, Gotto, Antonio M., additional, Ashraf, Tanya B., additional, McCrary Sisk, Christine, additional, Dansky, Hayes, additional, Mitchel, Yale, additional, Barter, Philip, additional, Gerstman, M., additional, Howes, L., additional, Kostner, K., additional, Nestel, P., additional, Sullivan, D., additional, Brath, H., additional, Patsch, J., additional, Paulweber, B., additional, Toplak, H., additional, Constance, C.M., additional, Howlett, E., additional, Mymin, D., additional, Pliamm, L., additional, Saunders, K.K., additional, Tardif, J.-C., additional, Tytus, R., additional, Aschner, P., additional, Keinänen-Klukaanniemi, S., additional, Strandberg, T., additional, Taskinen, M.-R., additional, Luc, G., additional, Richter, D., additional, Schlienger, J.L., additional, Zaïr, Y., additional, Appel, K.-F., additional, Baar, M., additional, Luley, C., additional, Overhoff, U., additional, Pomykaj, T., additional, Schaefer, T., additional, Lau, S.T., additional, Lee, K.L.F., additional, Tan, K., additional, Tomlinson, B., additional, Tsang, M.W., additional, Badacsonyi, K., additional, Kalina, Á., additional, Kanakaridisz, N., additional, Márk, L., additional, Péterfai, É., additional, Regos, L., additional, Reiber, I., additional, Takács, J., additional, Vértes, A., additional, Elis, A., additional, Gavish, D., additional, Harats, D., additional, Hussein, O., additional, Hayek, T., additional, Leitersdorf, E., additional, Bin Abdul Ghapar, A.K., additional, Chee, K.H., additional, Ismail, S.B., additional, Ling, K.H., additional, Ramanathan, G.R.L., additional, Sim, K.H., additional, Alvarado, R., additional, Benavides, M., additional, Cardona, G.E., additional, Gonzalez, G., additional, Verdejo, J., additional, Basart, D.C.G., additional, Imholz, B.P.M., additional, Jonker, J.J.C., additional, Nierop, P.R., additional, Posma, J.L., additional, Twickler, Th.B., additional, Barrington-Ward, E., additional, Cutfield, R., additional, Friedlander, D.H., additional, Scott, R.S., additional, Istad, H., additional, Langslet, G., additional, Skjelvan, G.K., additional, Campodónico Hoyos, S.J., additional, Coloma Araniya, R., additional, Gallegos C., A., additional, Pino Morales, C.A., additional, Watanabe, L., additional, Arutyunov, G.P., additional, Blokhin, A.B., additional, Bubnova, M.G., additional, Marcevich, S.Y., additional, Álvarez Sánchez, C., additional, Álvarez-Sala Walther, L.A., additional, Gil Extremera, B., additional, Perez Jimenez, F., additional, de Teresa Parreño, L., additional, Anderberg, C.-P., additional, Hedin, U., additional, Hellberg, A., additional, Höök, P., additional, Kjellström, T., additional, Nilsson, P., additional, Olsson, A.G., additional, Rosenqvist, U., additional, Tolagen, K., additional, Wolff, T., additional, Baskin, A., additional, Bays, H.E., additional, Bernstein, R.I., additional, Bittar, N., additional, Brinton, E.A., additional, Chee, L.H.K., additional, Cottiero, R.A., additional, D'Agostino, R.D., additional, Davidson, M.H., additional, Denker, P.S., additional, Garcia, R.K., additional, Hippert, R.K., additional, Isakov, T., additional, Kaster, S.R., additional, Kerzner, B., additional, Klein, E.J., additional, Koren, M.J., additional, Kutner, M.E., additional, Liljenquist, D., additional, Lorch, D.G., additional, Lorraine, R., additional, Lubin, B.C., additional, Lunde, N.M., additional, Majchrzak, T.J., additional, McKenney, J.M., additional, Mukherjee, S., additional, Muse, D.D., additional, Otruba, M.S., additional, Pappas, J.E., additional, Patrick, K., additional, Powell, S.J., additional, Riffer, E., additional, Rink, L.D., additional, Rohlf, J.L., additional, Rosen, J.B., additional, Rosenbilt, P.D., additional, Roth, E.M., additional, Rubenstein, C.J., additional, Rubino, J., additional, Rudolph, L.A., additional, Schneider, A., additional, Short, W.G., additional, Silverfield, J.C., additional, Suresh, D.P., additional, Tarshis, G.A., additional, Toth, P.D., additional, Townsend, R.W., additional, and Wahl, T.O., additional

Published
2015
Full Text
View/download PDF

46. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia

Author

Farnier,Michel, Chen,Erluo, Johnson-Levonas,Amy O, McCrary Sisk,Christine, Mitchel,Yale B, Farnier,Michel, Chen,Erluo, Johnson-Levonas,Amy O, McCrary Sisk,Christine, and Mitchel,Yale B

Abstract

Michel Farnier,1 Erluo Chen,2 Amy O Johnson-Levonas,2 Christine McCrary Sisk,2 Yale B Mitchel21Point Médical, Dijon, France; 2Merck and Co, Inc., Whitehouse Station, NJ, USABackground: Statins modify correlations between apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) and apoB and non-high-density lipoprotein cholesterol (non-HDL-C); however, it is not known whether niacin-based therapies have similar effects.Objective: To evaluate the effects of extended-release niacin (ERN)/laropiprant (LRPT), simvastatin (SIMVA), and ERN/LRPT + SIMVA (pooled ERN/LRPT + SIMVA) on apoB:LDL-C and apoB:non-HDL-C correlations in dyslipidemic patients.Methods: This post-hoc analysis of a 12-week study evaluated the apoB:LDL-C and apoB:non-HDL-C correlations in dyslipidemic patients randomized equally to double-blind ERN/LRPT 1 g/20 mg, SIMVA 10, 20, or 40 mg, or ERN/LRPT 1 g/20 mg + SIMVA (10, 20, or 40 mg) once daily for 4 weeks. At week 5, doses were doubled in all groups except SIMVA 40 mg (unchanged) and ERN/LRPT 1 g/20 mg + SIMVA 40 mg (switched to ERN/LRPT 2 g/40 mg + SIMVA 40 mg). Simple linear regression analyses were used to calculate LDL-C and non-HDL-C levels corresponding to known apoB baseline values (ie, in untreated patients) and following treatment.Results: The apoB:LDL-C and apoB:non-HDL-C correlations were higher and the predicted LDL-C and non-HDL-C levels for a known apoB value were considerably lower following treatment with ERN/LRPT, SIMVA and ERN/LRPT + SIMVA compared with untreated patients at baseline.Conclusion: Greater dissociation of apoB, LDL-C, and non-HDL-C targets occur following treatment with ERN/LRPT, SIMVA, and ERN/LRPT + SIMVA in patients with dyslipidemia. The achievement of more aggressive LDL-C and non-HDL-C goals in patients receiving lipid-modifying therapy may further reduce coronary risk by normalizing apoB-containing atherogenic lipoproteins.Keywords: apoB, LDL-C, non-HDL-C

Published
2014

47. Abstract 9613: Randomized Evaluation of Anacetrapib Lipid-Modifying Therapy in Patients With HeteroZygous Familial HypercholesterolEmia (REALIZE Study)

Author

Kastelein, John J, primary, Besseling, Joost, additional, Shah, Sukrut, additional, Bergeron, Jean, additional, Langslet, Gisle, additional, Hovingh, G Kees, additional, Al-Saady, Naab, additional, Koeijvoets, Michiel, additional, Hunter, John, additional, Johnson-Levonas, Amy O, additional, Fable, Jennifer, additional, Sapre, Aditi, additional, and Mitchel, Yale, additional

Published
2014
Full Text
View/download PDF

49. EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL

Author

Gotto, Antonio, primary, Chatterjee, Manash Shankar, additional, Liu, Yang, additional, Li, Xiujiang Susie, additional, Vaidya, Sanskruti, additional, Kher, Uma, additional, Cannon, Christopher, additional, Brinton, Eliot, additional, Davidson, Michael, additional, Moon, Jennifer, additional, Shah, Sukrut, additional, Dansky, Hayes, additional, Mitchel, Yale, additional, and Barter, Philip, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results